BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Expected to Announce Quarterly Sales of $63.92 Million

Equities research analysts predict that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Rating) will post $63.92 million in sales for the current quarter, according to Zacks. Five analysts have made estimates for BioCryst Pharmaceuticals’ earnings, with estimates ranging from $59.15 million to $66.95 million. BioCryst Pharmaceuticals posted sales of $49.96 million during the same quarter last […]

Related Keywords

United States ,Canada ,America ,Helenm Thackray , ,Biocryst Pharmaceuticals Company Profile Get Rating ,Zacks Investment Research ,Nasdaq ,Vanguard Group Inc ,Biocryst Pharmaceuticals ,Biocryst Pharmaceuticals Inc ,Barclays ,Royal Bank ,Fisher Asset Management ,Get Rating ,Biocryst Pharmaceutical ,Cryst Pharmaceuticals ,Investment Research ,Street Corp ,Asset Management ,Sarissa Capital Management ,Capital Management ,Cryst Pharmaceuticals Company Profile ,Nasdaq Bcrx ,Bcrx ,Medical ,09058v10 ,Ratings ,Consensus ,